This platform is currently totally free and created by doctors. 🩺
Menu
SpecialtiesDrug IndexGuidelinesClassificationsPricing
Login
HomeDrug IndexClinical Monograph

Norepinephrine: Uses, Dosage, Side Effects & Mechanism | DrugsAtlas

Authoritative Clinical Reference

Navigation

DRUG NAME: Norepinephrine
Therapeutic Class: Vasopressor
Subclass: Sympathomimetic catecholamine
Speciality: Critical Care Medicine
Schedule (India): Schedule H
Route(s): Intravenous (IV)
Formulations Available in India:
  • Injection: 1 mg/mL ampoule (available as 4 mg/4 mL or 2 mg/2 mL ampoules)
  • Supplied as norepinephrine bitartrate (equivalent to norepinephrine base strength 1 mg/mL on reconstitution)

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

▶ 1. Septic Shock (First-line vasopressor per ICMR/AIIMS guidelines)
Parameter Recommendation
Starting dose
 0.05–0.1 mcg/kg/min continuous IV infusion
Titration
 Increase by 0.02–0.05 mcg/kg/min every 5–15 minutes to achieve target MAP ≥65 mmHg
Usual maintenance dose
 0.1–0.3 mcg/kg/min
Maximum dose
 Up to 3 mcg/kg/min in refractory shock (specialist ICU setting only)
Clinical Notes:
  • Requires central venous access if used >48 hours or at medium/high doses
  • Always dilute in 5% Dextrose or Normal Saline (typical preparation: 4 mg in 100 mL)
  • Never administer as bolus — continuous infusion only
  • Ensure adequate fluid resuscitation prior to initiation
▶ 2. Other Vasodilatory Shock States (Neurogenic, Anaphylactic, Post-cardiopulmonary bypass)
Parameter Recommendation
Starting dose
 0.05–0.1 mcg/kg/min continuous IV infusion
Titration
 Increase by 0.02–0.05 mcg/kg/min every 5–15 minutes based on MAP response
Usual maintenance dose
 0.1–0.3 mcg/kg/min
Maximum dose
 Up to 2 mcg/kg/min (specialist supervision)
Clinical Notes:
  • Used as adjunct to volume resuscitation
  • May be combined with other agents as clinically appropriate
  • Specialist/ICU use only

Secondary Indications — Adults Only (Off-label)

Indication Dosing Duration Notes
Acute hypotension secondary to spinal anaesthesia — OFF-LABEL
 Starting dose: 0.05–0.1 mcg/kg/min IV infusion; Titration: Based on BP response; Maximum: 0.3 mcg/kg/min ≤1 hour typically Specialist only. Used in selected obstetric anaesthesia settings. Evidence: Indian anaesthesia practice
Cardiogenic shock with low SVR — OFF-LABEL
 Starting dose: 0.05 mcg/kg/min; Titration: As per septic shock protocol; Usual maintenance: 0.1–0.2 mcg/kg/min Until haemodynamic stability Specialist only. Used in combination with inotropes (e.g., dobutamine). Evidence: Indian cardiology ICU protocols

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

▶ Septic Shock / Refractory Hypotensive Shock
Age Group Starting Dose Titration Usual Maintenance Maximum Dose
Neonates
 0.05 mcg/kg/min IV Increase by 0.02 mcg/kg/min every 10–15 min 0.05–0.3 mcg/kg/min 1 mcg/kg/min
Infants and Children
 0.05–0.1 mcg/kg/min IV Increase by 0.02–0.05 mcg/kg/min every 10–15 min 0.1–0.5 mcg/kg/min 2 mcg/kg/min
Safety Monitoring:
  • Continuous HR, BP, and perfusion monitoring mandatory
  • Monitor for arrhythmias, peripheral perfusion (capillary refill, extremity colour)
  • Serial serum lactate measurement
  • Central venous access preferred for infusion duration >6 hours

Secondary Indications — Paediatrics (Off-label)

Not applicable.
  • NOT RECOMMENDED for routine intraoperative hypotension in children
  • Use restricted to intensive care under paediatric intensivist supervision only
Age Restrictions:
  • Not recommended below neonatal age except in NICU/PICU with cardiology review and specialist supervision

RENAL ADJUSTMENT

Renal Function Recommendation
All stages of renal impairment No dose adjustment required
Haemodialysis No specific adjustment; monitor closely
Clinical Note: Monitor renal perfusion and urine output — norepinephrine may reduce renal blood flow at high doses.

HEPATIC ADJUSTMENT

Severity Recommendation
Mild impairment
 No dose adjustment required
Moderate impairment
 No dose adjustment required; monitor response closely
Severe impairment
 Use with caution; altered response possible due to reduced catecholamine metabolism; specialist supervision recommended

CONTRAINDICATIONS

  • Uncorrected hypovolaemia (must ensure adequate fluid resuscitation first)
  • Mesenteric or peripheral arterial thrombosis (risk of vasoconstriction-induced ischaemia)
  • Known hypersensitivity to norepinephrine or formulation excipients
  • Profound hypoxia or hypercarbia (unless corrected)

CAUTIONS

  • Initiate only after adequate fluid resuscitation unless contraindicated
  • Prolonged use at high doses — risk of tissue ischaemia (digital, mesenteric, skin)
  • Extravasation risk — causes severe local necrosis; central venous access strongly preferred
  • Pre-existing severe hypertension — use with extreme caution
  • Thyrotoxicosis — enhanced sensitivity to catecholamines
  • Pre-existing arrhythmias or cardiac conduction defects
  • Concurrent use of drugs that sensitise myocardium to catecholamines (halogenated anaesthetics)
  • Peripheral IV use — acceptable only for <6 hours with close monitoring for extravasation

PREGNANCY

Aspect Details
Overall safety
 Limited data in pregnancy; use with caution
When to use
 Maternal septic shock or life-threatening hypotension where benefit clearly outweighs risk
Preferred alternatives
 Phenylephrine for obstetric hypotension (better uterine perfusion profile)
Monitoring required
 Maternal MAP, fetal heart rate, uterine blood flow (if feasible)

LACTATION

Aspect Details
Compatibility
 Compatible with breastfeeding — minimal systemic exposure
Expected levels in milk
 Negligible (short half-life, IV use in acute setting only)
Preferred alternatives
 Not applicable — used only in acute ICU settings
Infant monitoring
 Feeding pattern, irritability (though risk is low)

ELDERLY

Aspect Recommendation
Starting dose
 0.05 mcg/kg/min (lower end of range)
Titration
 Slower titration advised — increased sensitivity to vasopressors
Extra risks
 Arrhythmias, myocardial ischaemia, digital/peripheral ischaemia, compromised organ perfusion, renal impairment
Monitoring
 Closer BP, HR, ECG, and perfusion monitoring; assess renal function frequently

MAJOR DRUG INTERACTIONS

Interacting Drug Effect/Risk Management
MAO inhibitors (including linezolid)
 Severe hypertensive crisis due to impaired catecholamine metabolism Avoid concomitant use; if unavoidable, use significantly reduced doses with intensive monitoring
Tricyclic antidepressants (TCAs)
 Potentiated hypertensive and arrhythmogenic effects Avoid combination or use with extreme caution; reduce norepinephrine dose
Halogenated general anaesthetics (halothane, enflurane)
 Increased risk of ventricular arrhythmias due to myocardial sensitisation Avoid concurrent use; use alternative anaesthetics if vasopressor needed
Ergot alkaloids
 Severe vasoconstriction; risk of gangrene Avoid combination

MODERATE DRUG INTERACTIONS

Interacting Drug Effect/Risk Management
Beta-blockers
 May attenuate chronotropic response; risk of unopposed alpha-mediated vasoconstriction and reflex bradycardia Monitor HR closely; consider alternative vasopressor if significant bradycardia
Diuretics
 Hypovolaemia may alter vasopressor response Optimise volume status before initiating norepinephrine
Digoxin
 Additive risk of arrhythmias Monitor ECG; watch for ectopic beats
Antihypertensives
 Antagonised effects; may require higher norepinephrine doses Assess haemodynamic response; titrate accordingly
Oxytocin
 Additive hypertensive effect in obstetric settings Monitor BP closely when co-administered

COMMON ADVERSE EFFECTS

  • Reflex bradycardia (due to baroreceptor activation)
  • Hypertension (dose-related)
  • Peripheral vasoconstriction (cold extremities, pallor)
  • Headache
  • Anxiety or restlessness
  • Nausea (less common)

SERIOUS ADVERSE EFFECTS

Adverse Effect Notes
Severe tissue necrosis from extravasation Requires immediate local infiltration with phentolamine (5–10 mg in 10–15 mL NS); discontinue peripheral infusion
Cardiac arrhythmias Ventricular ectopics, tachyarrhythmias — especially with high doses or concurrent sensitising agents
Digital/limb ischaemia Prolonged use at high doses; may require dose reduction or alternative vasopressor
Mesenteric ischaemia Monitor for abdominal pain, bloody stools; reduce dose or discontinue
Hypertensive crisis Rare; dose-related; immediate dose reduction required
Myocardial ischaemia Monitor ECG for ST changes; consider in patients with coronary artery disease

MONITORING REQUIREMENTS

Timing Parameters
Baseline
 Blood pressure, heart rate, ECG, perfusion status (capillary refill, extremity temperature), serum lactate, volume status (CVP if available), central venous access confirmation
During initiation/dose change
 Continuous arterial BP monitoring (preferred) or frequent non-invasive BP (every 5–15 min during titration); HR; ECG; peripheral perfusion assessment; urine output hourly
Long-term (if prolonged infusion)
 Monitor for extravasation at IV site; peripheral and digital perfusion; renal function (creatinine, urine output); lactate clearance; daily assessment of vasopressor weaning readiness

BRANDS AVAILABLE IN INDIA

  • Levophed (Abbott)
  • Norsol (Neon Laboratories)
  • Adrenor (Samarth Pharma)
  • Noradrenalin (Various manufacturers)
  • Norsup (Sun Pharma)
Note: Usually available as norepinephrine bitartrate equivalent to 1 mg/mL norepinephrine base.

PRICE RANGE (INR)

Formulation Price Range Notes
4 mg/4 mL ampoule ₹40–₹90 per ampoule Brand-dependent variation
2 mg/2 mL ampoule ₹25–₹50 per ampoule Less commonly stocked
  • Under NLEM 2022 — Price controlled (vasopressor category)
  • Government supply available in most tertiary care setups

CLINICAL PEARLS

  1. Always administer via continuous infusion — never as bolus — rapid bolus can cause severe hypertension and arrhythmias.
  2. Central line preferred — peripheral IV acceptable only for <6 hours with close extravasation monitoring; if extravasation occurs, infiltrate area immediately with phentolamine.
  3. Ensure adequate fluid resuscitation first — norepinephrine in hypovolaemic patients causes excessive vasoconstriction without improving perfusion.
  4. Avoid prolonged high doses — widespread vasoconstriction at doses >1 mcg/kg/min may worsen organ perfusion despite achieving target MAP.
  5. In cardiogenic shock with low SVR — combine with an inotrope (e.g., dobutamine) rather than escalating norepinephrine alone.
  6. Pale or white extremities — indicates excessive vasoconstriction; reassess dose and consider addition of low-dose vasopressin to allow norepinephrine reduction.

TAGS

norepinephrine; noradrenaline; vasopressor; septic shock; ICU; catecholamine; critical care; NLEM India; Schedule H; pregnancy-caution

VERSION

RxIndia v0.9 — 18 Feb 2026

REFERENCES

  • CDSCO product approvals
  • Indian Pharmacopoeia (IP)
  • National Formulary of India (NFI)
  • NLEM India 2022
  • ICMR Guidelines on Sepsis and Shock
  • AIIMS ICU Protocols
  • API Textbook of Medicine
  • IAP Critical Care Guidelines (for paediatric dosing)
  • Harrison’s Principles of Internal Medicine (pharmacology reference)
⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

All feedback is reviewed by our clinical editorial team.